lonafarnib has been researched along with d-alpha tocopherol in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (d-alpha tocopherol) | Trials (d-alpha tocopherol) | Recent Studies (post-2010) (d-alpha tocopherol) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 32,198 | 2,903 | 7,258 |
| Protein | Taxonomy | lonafarnib (IC50) | d-alpha tocopherol (IC50) |
|---|---|---|---|
| Glutathione S-transferase P | Homo sapiens (human) | 0.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coan, AD; Desjardins, A; Friedman, AH; Friedman, HS; Herndon, JE; Peters, KB; Reardon, DA; Threatt, S; Vredenburgh, JJ | 1 |
1 trial(s) available for lonafarnib and d-alpha tocopherol
| Article | Year |
|---|---|
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carotenoids; Dacarbazine; Disease-Free Survival; Drug Combinations; Enzyme Inhibitors; Fatty Acids, Unsaturated; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Piperidines; Pyridines; Temozolomide; Vitamin E | 2011 |